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OBJECTIVES: To evaluate the impact of the first selective 
cannabinoid type 1 (CB1) receptor blocker, rimonabant, developed 
for the management of cardiometabolic risk factors, on 
health related quality of life (HRQOL).  
METHODS: Over 6600overweight/obese patients, with or without comorbidities were 
randomized in double-blind, placebo-controlled, 2 fixed doses (5 
mg and 20mg), parallel-group clinical trials. Patients completed 
the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and 
the Short-Form Health Survey (SF-36) questionnaires at baseline 
and every 3 months up to 1 year. The IWQOL-Lite is a validated 
31-item self-reported questionnaire specifically designed for 
HRQOL assessment in obesity and comprises 5 domains and a 
total score. SF-36 is a standardized generic HRQOL measure 
used in general population (non-specific for obesity). Analyses 
presented were performed on mean score changes from baseline 
to 1 year in the intent-to-treat population.  
RESULTS: At 1 year,patients administered rimonabant 20 mg once daily reported 
consistently greater improvement in IWQOL-Lite scores than 
patients in the placebo group in all domains (Physical Function, 
Self-esteem, Sexual Life, Public Distress, Work) and total score 
(p < 0.001, except Work, p = 0.03). SF-36 provided statistically 
significant results for 5/8 domains (p < or = 0.05); 3 of them 
(Physical Functioning, Bodily Pain, General Health) supported 
greater improvement with rimonabant, while the other 2 (Role 
Emotional and Mental Health) were less decreased with placebo. 
Overall, HRQOL results appeared to be less clinically meaningful 
on the SF-36 [effect sizes (ES) ranging between 0.01 and 0.33, 
depending on the score considered] than on the IWQOL-Lite (ES 
between 0.22 and 0.45). 
 CONCLUSION: Using an obesityspecific 
questionnaire (IWQOL-Lite), rimonabant 20mg was 
associated with a significant and sustained improvement in 
HRQOL up to 1 year. As expected, SF-36 appeared to be less 
sensitive to clinical changes in this overweight/obese population. 
 
